129 related articles for article (PubMed ID: 29631213)
1. Label-Free Quantitative Proteomics Unravels Carboxypeptidases as the Novel Biomarker in Pancreatic Ductal Adenocarcinoma.
Song Y; Wang Q; Wang D; Junqiang Li ; Yang J; Li H; Wang X; Jin X; Jing R; Yang JH; Su H
Transl Oncol; 2018 Jun; 11(3):691-699. PubMed ID: 29631213
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis.
Kawamoto M; Kohi S; Abe T; Dbouk M; Macgregor-Das A; Koi C; Song KB; Borges M; Sugimine R; Laheru D; Hruban RH; Roberts N; Klein AP; Goggins M
Int J Cancer; 2022 Apr; 150(7):1123-1133. PubMed ID: 34817877
[TBL] [Abstract][Full Text] [Related]
3. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the pancreatic secretory enzymes
Tamura K; Yu J; Hata T; Suenaga M; Shindo K; Abe T; MacGregor-Das A; Borges M; Wolfgang CL; Weiss MJ; He J; Canto MI; Petersen GM; Gallinger S; Syngal S; Brand RE; Rustgi A; Olson SH; Stoffel E; Cote ML; Zogopoulos G; Potash JB; Goes FS; McCombie RW; Zandi PP; Pirooznia M; Kramer M; Parla J; Eshleman JR; Roberts NJ; Hruban RH; Klein AP; Goggins M
Proc Natl Acad Sci U S A; 2018 May; 115(18):4767-4772. PubMed ID: 29669919
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
Chung JC; Oh MJ; Choi SH; Bae CD
ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
[TBL] [Abstract][Full Text] [Related]
6. Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues.
Atay S
PeerJ; 2020; 8():e10141. PubMed ID: 33194391
[TBL] [Abstract][Full Text] [Related]
7. Variants in pancreatic carboxypeptidase genes CPA2 and CPB1 are not associated with chronic pancreatitis.
Nakano E; Geisz A; Masamune A; Niihori T; Hamada S; Kume K; Kakuta Y; Aoki Y; Matsubara Y; Ebert K; Ludwig M; Braun M; Groneberg DA; Shimosegawa T; Sahin-Tóth M; Witt H
Am J Physiol Gastrointest Liver Physiol; 2015 Oct; 309(8):G688-94. PubMed ID: 26316592
[TBL] [Abstract][Full Text] [Related]
8. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
[TBL] [Abstract][Full Text] [Related]
9. Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.
Liu L; Wang S; Cen C; Peng S; Chen Y; Li X; Diao N; Li Q; Ma L; Han P
Mol Med Rep; 2019 Aug; 20(2):1901-1914. PubMed ID: 31257501
[TBL] [Abstract][Full Text] [Related]
10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
11. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
12. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma.
Li H; Wang X; Fang Y; Huo Z; Lu X; Zhan X; Deng X; Peng C; Shen B
Oncotarget; 2017 Aug; 8(32):52571-52583. PubMed ID: 28881752
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
14. Chymotrypsin C is a co-activator of human pancreatic procarboxypeptidases A1 and A2.
Szmola R; Bence M; Carpentieri A; Szabó A; Costello CE; Samuelson J; Sahin-Tóth M
J Biol Chem; 2011 Jan; 286(3):1819-27. PubMed ID: 21098023
[TBL] [Abstract][Full Text] [Related]
15. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
[TBL] [Abstract][Full Text] [Related]
16. High expression of RACK1 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma.
Han H; Wang D; Yang M; Wang S
Oncol Lett; 2018 Feb; 15(2):2073-2078. PubMed ID: 29434907
[TBL] [Abstract][Full Text] [Related]
17. Candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method.
Lin Y; Jin Y; Lin LJ; Cao Y; Zhang Y; Chen SF; Zheng CQ
Gene; 2014 May; 540(2):232-7. PubMed ID: 24561286
[TBL] [Abstract][Full Text] [Related]
18. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
19. Microarray Analysis of the Expression Profile of Long Non-Coding RNAs Indicates lncRNA RP11-263F15.1 as a Biomarker for Diagnosis and Prognostic Prediction of Pancreatic Ductal Adenocarcinoma.
Huang X; Ta N; Zhang Y; Gao Y; Hu R; Deng L; Zhang B; Jiang H; Zheng J
J Cancer; 2017; 8(14):2740-2755. PubMed ID: 28928863
[TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
